Phase I Dose Escalation of Doxorubicin Chemotherapy in Tumor-Bearing Equidae
Article first published online: 26 JUL 2013
Copyright © 2013 by the American College of Veterinary Internal Medicine
Journal of Veterinary Internal Medicine
Volume 27, Issue 5, pages 1209–1217, September/October 2013
How to Cite
Théon, A.P., Pusterla, N., Magdesian, K.G. and Wilson, W.D. (2013), Phase I Dose Escalation of Doxorubicin Chemotherapy in Tumor-Bearing Equidae. Journal of Veterinary Internal Medicine, 27: 1209–1217. doi: 10.1111/jvim.12145
- Issue published online: 13 SEP 2013
- Article first published online: 26 JUL 2013
- Manuscript Accepted: 4 JUN 2013
- Manuscript Revised: 15 APR 2013
- Manuscript Received: 12 NOV 2012
- Cunningham and Doyle Charitable Trust Fund
- UC Davis Center for Equine Health
- Oncology treatment
There is no information on the use of doxorubicin in horses with tumors.
To determine dose-limiting toxicosis (DLT) and maximum tolerated dose (MTD) of doxorubicin in tumor-bearing horses.
Seventeen horses with 34 localized or multicentric advanced tumors.
Two-stage dose-ranging design involving intrapatient and interpatient dose escalation. Treatment protocol included 6 treatment cycles given at 3-week intervals with dosages ranging from 40 to 85 mg/m2. Clinical signs, hematologic, and nonhematologic changes were evaluated.
Total doses ranged from 1,127 to 2,900 mg in 12 horses that completed the assigned treatment protocols. The MTD was 75 mg/m2. Hypersensitivity reactions and neutropenia were dose limiting. Hypersensitivity was dose-dependent but schedule invariant. Neutropenia was dose- and cycle-dependent but dose-escalation schedule invariant. Cardiotoxicity was not observed.
Conclusion and Clinical Relevance
The recommended dosage of doxorubicin to treat horses is 70 mg/m2 given at 3-week intervals as single agent. Adjunctive treatment with antihistamines and nonsteroidal anti-inflammatory drugs is recommended to control hypersensitivity.